About Foghorn Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://foghorntx.com/
Frequently Asked Questions
What is the 52-week range for FHTX?
The 52-week high is $7.61 and the 52-week low is $1.79.
What is the P/E ratio for FHTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for FHTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -301.61%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -175.78%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2666.96.
Analyst Recommendation Trends
Wall Street analyst consensus for FHTX over the last few months:
Latest FHTX News
Friday's session: top gainers and losers
Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis.
FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
Wedbush downgraded Foghorn to ‘Neutral’ from ‘Outperform,’ stating that its bullish thesis no longer applies after the partnership with Lilly ended.
These stocks are moving in today's session
Curious to know what's happening on the US markets in the middle of the day on Friday? Join us as we explore the top gainers and losers in today's session.
Friday's session: gap up and gap down stocks
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
The companies are scrapping two collaborative cancer programs and don't anticipate any further joint projects
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock rose
Correction: Top Midday Decliners
(Corrects the first paragraph to indicate the federal court denied California's request to temporari
Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2
Wedbush analyst Robert Driscoll downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Outperform to Neutral and lowers the price target from $10 to $2.
TD Cowen Downgrades Foghorn Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Hold.
Guggenheim Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $12 to $5.
Abbott To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
This AST SpaceMobile Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded FHTX, BUSE, ASTS, ATRC and EQBK; targets fell for BUSE, ASTS and EQBK but rose for ATRC.
HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.
BTIG Downgrades Foghorn Therapeutics to Neutral
BTIG analyst Jeet Mukherjee downgrades Foghorn Therapeutics (NASDAQ:FHTX) from Buy to Neutral.
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 1% and th
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
Foghorn Therapeutics and Eli Lilly don’t plan any future collaborations following the dissolution of a cancer-drug partnership.
Top Midday Decliners
Corteva (CTVA) said Thursday that a federal court in California denied its request to temporarily bl
Which stocks are experiencing notable movement on Thursday?
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal
Foghorn Therapeutics Inc. (NASDAQ:FHTX) stock is trading lower on Thursday with a session volume of 9.158 million, compared to the average volume of 377.206 thousand, as per Benzinga Pro data. End of Eli Lilly Collaboration and FHD-909 Development Following a review of Phase 1 data for FHD-909 (LY4050784), Foghorn and Eli Lilly & Co. (NYSE:LLY) will not advance the program into clinical development expansion. The companies also will not advance their Selective SMARCA2 degrader program and do not
Lilly, Foghorn part ways; Wave’s FDA-approved plans
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Thursday's session: gap up and gap down stocks
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review
Foghorn and Lilly will end further collaboration activities after FHD-909 failed to demonstrate sufficient efficacy, while Foghorn cuts its workforce by approximately 40% and extends its cash runway into the second half of 2029. Key Investor TakeawaysFoghorn Therapeutics (NASDAQ:FHTX) and Lilly decided not to advance FHD-909 into clinical expansion following a review of Phase 1 dose-escalation data.
Nasdaq Gains 100 Points; ISM manufacturing PMI Slips In September
U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Corteva plunged 84%.
FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?
Foghorn and Eli Lilly decided to stop developing FHD-909 after reviewing Phase 1 clinical data.
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's regular session. The company's market cap stands at $3.5 million. Stablecoin Development (AMEX:SDEV) stock rose
These stocks that are showing activity before the opening bell on Thursday.
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Dow Falls Over 200 Points; Micron Earnings Top Views
U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estimates, and European markets declined.
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass.,
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV) shares moved
Foghorn Therapeutic Announces That The Company And Lilly Will Not Advance The FHD-909 Program Into The Clinical Development Expansion Phase
Following a review of clinical data from the Phase 1 dose escalation trial of FHD-909 (LY4050784), Foghorn and Lilly have decided not to advance the program into the clinical development expansion phase. The
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-24 | Gallagher Neil | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | Duty Stuart | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | Mendelsohn Michael | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | Biller Scott | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | Cole Douglas G. | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | Lynch Thomas J. Jr. | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | SMITH IAN F | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | GILL SIMBA | +28,000 | $4.08 | $114,240 |
| 2026-06-24 | PARSHALL B LYNNE | +28,000 | $4.08 | $114,240 |
| 2026-04-10 | GOTTSCHALK ADRIAN | +59,208 | - | - |
| 2026-04-10 | GOTTSCHALK ADRIAN | -59,208 | - | - |
| 2026-04-09 | GOTTSCHALK ADRIAN | +47,497 | - | - |
| 2026-04-09 | GOTTSCHALK ADRIAN | -47,497 | - | - |
| 2026-02-23 | Maynard Ryan D | +400,000 | $5.75 | $2,300,000 |
| 2026-02-05 | GOTTSCHALK ADRIAN | +1,075,000 | $5.23 | $5,622,250 |
| 2026-01-30 | Rivkin Anna | +165,000 | $5.71 | $942,150 |
| 2026-01-30 | Costa Carlos | +230,000 | $5.71 | $1,313,300 |
| 2026-01-30 | LaCascia Michael | +295,000 | $5.71 | $1,684,450 |
| 2026-01-30 | Bellon Steven F. | +300,000 | $5.71 | $1,713,000 |
| 2026-01-30 | Cardama Alfonso Quintas | +300,000 | $5.71 | $1,713,000 |
| 2026-01-13 | AFEYAN NOUBAR | +1,117,734 | - | - |
| 2026-01-13 | AFEYAN NOUBAR | +1,117,734 | - | - |
| 2026-01-13 | AFEYAN NOUBAR | +2,235,468 | $6.7099 | $14,999,767 |